Treatment and prevention of antibiotic associated diarrhea

International Journal of Antimicrobial Agents

Volumn 16, Issue 4, 2000, Pages 521-526

  Bergogne Berezin E ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antibiotic associated diarrhea; Biotherapeutic agents; Intestinal ecosystem; Saccharomyces boulardii

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BACITRACIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COLESTIPOL; COTRIMOXAZOLE; CYTOTOXIN; ENTEROTOXIN; FUSIDIC ACID; METRONIDAZOLE; PROBIOTIC AGENT; QUINOLONE DERIVATIVE; TEICOPLANIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BIFIDOBACTERIUM LONGUM; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLONY FORMING UNIT; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCOCCUS FAECIUM; HOSPITAL HYGIENE; HUMAN; INTENSIVE CARE UNIT; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RELAPSE; RISK FACTOR; SACCHAROMYCES BOULARDII;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INTESTINES; LACTOBACILLUS CASEI; PROBIOTICS; RISK FACTORS; SACCHAROMYCES;

EID: 0033675729     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00293-4     Document Type: Article

References (25)

1. Antibiotic-associated pseudomembranous colitis due to toxin producing Clostridia
2. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea
3. Antibiotic-associated diarrhea, Clostridium difficile, and short-chain fatty acids
4. Les diarrhees de l'antibiotherapie
5. Recurrent Clostridium difficile disease: Epidemiology and clinical characteristics
6. Mechanisms and management of antibiotic-associated diarrhea
7. Les colites pseudomembraneuses associees a l'antibiotherapie
8. Review article: Treatment of Clostridium difficile infection
9. Pseudomembranous colitis: Causes and cures
10. Utilisation des probiotiques chez l'homme
11. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections
12. Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhea
13. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants
14. A double-blind, placebo-controlled study of the efficacy of lactinex in the prophylaxis of amoxicillin-induced diarrhea
15. Yoghurt with Bifidobacterium longum reduces erythromycin-induced gastrointestinal effects
16. Prevention of antibiotic-associated diarrhea utilizing Lactobacillus GG
17. Essais cliniques controles en double insu de l'Ultra-Levure lyophilisee. Etude multicentrique par 25 medecins de 388 cas
18. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study
19. Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo
20. Impact ecologique de l'antibiotherapie. Place des microorganismes de substitution dans le controle des diarrhees et colites associees aux antibiotiques
21. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG
22. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG
23. Essai clinique randomise, a double insu contre placebo, de Saccharomyces boulardii en association a une antibiotherapie standard dans le traitement de l'infection a Clostridium difficile
24. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa
25. Living in the 'post-antibiotic era': Could the use of probiotics be an effective strategy?